APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hemophilia Medication

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Hemophilia Medication Industry Growth and Trends Forecast to 2032

31 December 2025115 pages

Choose your research edition.

Industry ResearchHemophilia Medication Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemophilia Medication Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Hemophilia Medication Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemophilia Medication Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemophilia Medication Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Hemophilia Medication market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Hemophilia Medication is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Hemophilia Medication is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hemophilia Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hemophilia Medication include Bio Products Laboratory (BPL), BioMarin Pharmaceutical, CSL Behring, Grifols, Kedrion Biopharma, LFB Group, Novo Nordisk, Octapharma and Takeda Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Hemophilia Medication market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Hemophilia Medication market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Hemophilia Medication market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Hemophilia Medication.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Hemophilia Medication market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Hemophilia Medication Market by Company

Bio Products Laboratory (BPL)

BioMarin Pharmaceutical

CSL Behring

Grifols

Kedrion Biopharma

LFB Group

Novo Nordisk

Octapharma

Takeda Pharmaceutical

Bayer

Gensciences

HuaLan Bio

Pfizer

Roche

Sanofi

Shanghai RAAS

Hemophilia Medication Segment by Type

Blood Products

Genetically Engineered Product

Hemophilia Medication Segment by Application

Hemophilia A

Hemophilia B

Hemophilia Medication Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemophilia Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia Medication.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hemophilia Medication manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Hemophilia Medication in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Blood Products Table 2. Major Company of Genetically Engineered Product Table 3. Global Hemophilia Medication Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Hemophilia Medication Sales by Type (2021-2026) & (K Units) Table 5. Global Hemophilia Medication Sales Market Share in Volume by Type (2021-2026) Table 6. Global Hemophilia Medication Sales by Type (2021-2026) & (US$ Million) Table 7. Global Hemophilia Medication Sales Market Share in Value by Type (2021-2026) Table 8. Global Hemophilia Medication Price by Type (2021-2026) & (US$/Unit) Table 9. Global Hemophilia Medication Sales by Type (2027-2032) & (K Units) Table 10. Global Hemophilia Medication Sales Market Share in Volume by Type (2027-2032) Table 11. Global Hemophilia Medication Sales by Type (2027-2032) & (US$ Million) Table 12. Global Hemophilia Medication Sales Market Share in Value by Type (2027-2032) Table 13. Global Hemophilia Medication Price by Type (2027-2032) & (US$/Unit) Table 14. North America Hemophilia Medication Sales by Type (2021-2026) & (K Units) Table 15. North America Hemophilia Medication Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Hemophilia Medication Sales by Type (2021-2026) & (K Units) Table 17. Europe Hemophilia Medication Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Hemophilia Medication Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Hemophilia Medication Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Hemophilia Medication Sales by Type (2021-2026) & (K Units) Table 21. Latin America Hemophilia Medication Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Hemophilia Medication Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Hemophilia Medication Sales by Type (2021-2026) & (US$ Million) Table 24. Hemophilia Medication Industry Trends Table 25. Hemophilia Medication Industry Drivers Table 26. Hemophilia Medication Industry Opportunities and Challenges Table 27. Hemophilia Medication Industry Restraints Table 28. Global Hemophilia Medication Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Hemophilia Medication Revenue Market Share by Company (2021-2026) Table 30. Global Hemophilia Medication Sales by Company (2021-2026) & (K Units) Table 31. Global Hemophilia Medication Sales Share by Company (2021-2026) Table 32. Global Hemophilia Medication Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Hemophilia Medication Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Hemophilia Medication Major Company Production Sites and Headquarters Table 35. Global Hemophilia Medication Company, Product Type & Application Table 36. Global Hemophilia Medication Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Hemophilia Medication by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Hemophilia Medication Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Hemophilia Medication Sales by Region (2021-2026) & (K Units) Table 41. Global Hemophilia Medication Sales Market Share in Volume by Region (2021-2026) Table 42. Global Hemophilia Medication Sales by Region (2021-2026) & (US$ Million) Table 43. Global Hemophilia Medication Sales Market Share in Value by Region (2021-2026) Table 44. Global Hemophilia Medication Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Hemophilia Medication Sales by Region (2027-2032) & (K Units) Table 46. Global Hemophilia Medication Sales Market Share in Volume by Region (2027-2032) Table 47. Global Hemophilia Medication Sales by Region (2027-2032) & (US$ Million) Table 48. Global Hemophilia Medication Sales Market Share in Value by Region (2027-2032) Table 49. Global Hemophilia Medication Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Hemophilia Medication Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Hemophilia Medication Sales by Application (2021-2026) & (K Units) Table 52. Global Hemophilia Medication Sales Market Share in Volume by Application (2021-2026) Table 53. Global Hemophilia Medication Sales by Application (2021-2026) & (US$ Million) Table 54. Global Hemophilia Medication Sales Market Share in Value by Application (2021-2026) Table 55. Global Hemophilia Medication Price by Application (2021-2026) & (US$/Unit) Table 56. Global Hemophilia Medication Sales by Application (2027-2032) & (K Units) Table 57. Global Hemophilia Medication Sales Market Share in Volume by Application (2027-2032) Table 58. Global Hemophilia Medication Sales by Application (2027-2032) & (US$ Million) Table 59. Global Hemophilia Medication Sales Market Share in Value by Application (2027-2032) Table 60. Global Hemophilia Medication Price by Application (2027-2032) & (US$/Unit) Table 61. North America Hemophilia Medication Sales by Application (2021-2026) & (K Units) Table 62. North America Hemophilia Medication Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Hemophilia Medication Sales by Application (2021-2026) & (K Units) Table 64. Europe Hemophilia Medication Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Hemophilia Medication Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Hemophilia Medication Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Hemophilia Medication Sales by Application (2021-2026) & (K Units) Table 68. Latin America Hemophilia Medication Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Hemophilia Medication Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Hemophilia Medication Sales by Application (2021-2026) & (US$ Million) Table 71. Bio Products Laboratory (BPL) Company Information Table 72. Bio Products Laboratory (BPL) Business Overview Table 73. Bio Products Laboratory (BPL) Hemophilia Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Bio Products Laboratory (BPL) Hemophilia Medication Product Portfolio Table 75. Bio Products Laboratory (BPL) Recent Development Table 76. BioMarin Pharmaceutical Company Information Table 77. BioMarin Pharmaceutical Business Overview Table 78. BioMarin Pharmaceutical Hemophilia Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. BioMarin Pharmaceutical Hemophilia Medication Product Portfolio Table 80. BioMarin Pharmaceutical Recent Development Table 81. CSL Behring Company Information Table 82. CSL Behring Business Overview Table 83. CSL Behring Hemophilia Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. CSL Behring Hemophilia Medication Product Portfolio Table 85. CSL Behring Recent Development Table 86. Grifols Company Information Table 87. Grifols Business Overview Table 88. Grifols Hemophilia Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Grifols Hemophilia Medication Product Portfolio Table 90. Grifols Recent Development Table 91. Kedrion Biopharma Company Information Table 92. Kedrion Biopharma Business Overview Table 93. Kedrion Biopharma Hemophilia Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Kedrion Biopharma Hemophilia Medication Product Portfolio Table 95. Kedrion Biopharma Recent Development Table 96. LFB Group Company Information Table 97. LFB Group Business Overview Table 98. LFB Group Hemophilia Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. LFB Group Hemophilia Medication Product Portfolio Table 100. LFB Group Recent Development Table 101. Novo Nordisk Company Information Table 102. Novo Nordisk Business Overview Table 103. Novo Nordisk Hemophilia Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Novo Nordisk Hemophilia Medication Product Portfolio Table 105. Novo Nordisk Recent Development Table 106. Octapharma Company Information Table 107. Octapharma Business Overview Table 108. Octapharma Hemophilia Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Octapharma Hemophilia Medication Product Portfolio Table 110. Octapharma Recent Development Table 111. Takeda Pharmaceutical Company Information Table 112. Takeda Pharmaceutical Business Overview Table 113. Takeda Pharmaceutical Hemophilia Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Takeda Pharmaceutical Hemophilia Medication Product Portfolio Table 115. Takeda Pharmaceutical Recent Development Table 116. Bayer Company Information Table 117. Bayer Business Overview Table 118. Bayer Hemophilia Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Bayer Hemophilia Medication Product Portfolio Table 120. Bayer Recent Development Table 121. Gensciences Company Information Table 122. Gensciences Business Overview Table 123. Gensciences Hemophilia Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Gensciences Hemophilia Medication Product Portfolio Table 125. Gensciences Recent Development Table 126. HuaLan Bio Company Information Table 127. HuaLan Bio Business Overview Table 128. HuaLan Bio Hemophilia Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. HuaLan Bio Hemophilia Medication Product Portfolio Table 130. HuaLan Bio Recent Development Table 131. Pfizer Company Information Table 132. Pfizer Business Overview Table 133. Pfizer Hemophilia Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Pfizer Hemophilia Medication Product Portfolio Table 135. Pfizer Recent Development Table 136. Roche Company Information Table 137. Roche Business Overview Table 138. Roche Hemophilia Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Roche Hemophilia Medication Product Portfolio Table 140. Roche Recent Development Table 141. Sanofi Company Information Table 142. Sanofi Business Overview Table 143. Sanofi Hemophilia Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Sanofi Hemophilia Medication Product Portfolio Table 145. Sanofi Recent Development Table 146. Shanghai RAAS Company Information Table 147. Shanghai RAAS Business Overview Table 148. Shanghai RAAS Hemophilia Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Shanghai RAAS Hemophilia Medication Product Portfolio Table 150. Shanghai RAAS Recent Development Table 151. North America Hemophilia Medication Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 152. North America Hemophilia Medication Sales by Country (2021-2026) & (K Units) Table 153. North America Hemophilia Medication Sales Market Share by Country (2021-2026) Table 154. North America Hemophilia Medication Sales Forecast by Country (2027-2032) & (K Units) Table 155. North America Hemophilia Medication Sales Market Share Forecast by Country (2027-2032) Table 156. North America Hemophilia Medication Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. North America Hemophilia Medication Market Size by Country (2021-2026) & (US$ Million) Table 158. North America Hemophilia Medication Market Share by Country (2021-2026) Table 159. North America Hemophilia Medication Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. North America Hemophilia Medication Market Share Forecast by Country (2027-2032) Table 161. Europe Hemophilia Medication Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 162. Europe Hemophilia Medication Sales by Country (2021-2026) & (K Units) Table 163. Europe Hemophilia Medication Sales Market Share by Country (2021-2026) Table 164. Europe Hemophilia Medication Sales Forecast by Country (2027-2032) & (K Units) Table 165. Europe Hemophilia Medication Sales Market Share Forecast by Country (2027-2032) Table 166. Europe Hemophilia Medication Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Europe Hemophilia Medication Market Size by Country (2021-2026) & (US$ Million) Table 168. Europe Hemophilia Medication Market Share by Country (2021-2026) Table 169. Europe Hemophilia Medication Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Europe Hemophilia Medication Market Share Forecast by Country (2027-2032) Table 171. Asia-Pacific Hemophilia Medication Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 172. Asia-Pacific Hemophilia Medication Sales by Country (2021-2026) & (K Units) Table 173. Asia-Pacific Hemophilia Medication Sales Market Share by Country (2021-2026) Table 174. Asia-Pacific Hemophilia Medication Sales Forecast by Country (2027-2032) & (K Units) Table 175. Asia-Pacific Hemophilia Medication Sales Market Share Forecast by Country (2027-2032) Table 176. Asia-Pacific Hemophilia Medication Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Asia-Pacific Hemophilia Medication Market Size by Country (2021-2026) & (US$ Million) Table 178. Asia-Pacific Hemophilia Medication Market Share by Country (2021-2026) Table 179. Asia-Pacific Hemophilia Medication Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Asia-Pacific Hemophilia Medication Market Share Forecast by Country (2027-2032) Table 181. Latin America Hemophilia Medication Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 182. Latin America Hemophilia Medication Sales by Country (2021-2026) & (K Units) Table 183. Latin America Hemophilia Medication Sales Market Share by Country (2021-2026) Table 184. Latin America Hemophilia Medication Sales Forecast by Country (2027-2032) & (K Units) Table 185. Latin America Hemophilia Medication Sales Market Share Forecast by Country (2027-2032) Table 186. Latin America Hemophilia Medication Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. Latin America Hemophilia Medication Market Size by Country (2021-2026) & (US$ Million) Table 188. Latin America Hemophilia Medication Market Share by Country (2021-2026) Table 189. Latin America Hemophilia Medication Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. Latin America Hemophilia Medication Market Share Forecast by Country (2027-2032) Table 191. Middle East and Africa Hemophilia Medication Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 192. Middle East and Africa Hemophilia Medication Sales by Country (2021-2026) & (K Units) Table 193. Middle East and Africa Hemophilia Medication Sales Market Share by Country (2021-2026) Table 194. Middle East and Africa Hemophilia Medication Sales Forecast by Country (2027-2032) & (K Units) Table 195. Middle East and Africa Hemophilia Medication Sales Market Share Forecast by Country (2027-2032) Table 196. Middle East and Africa Hemophilia Medication Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 197. Middle East and Africa Hemophilia Medication Market Size by Country (2021-2026) & (US$ Million) Table 198. Middle East and Africa Hemophilia Medication Market Share by Country (2021-2026) Table 199. Middle East and Africa Hemophilia Medication Market Size Forecast by Country (2027-2032) & (US$ Million) Table 200. Middle East and Africa Hemophilia Medication Market Share Forecast by Country (2027-2032) Table 201. Key Raw Materials Table 202. Raw Materials Key Suppliers Table 203. Hemophilia Medication Distributors List Table 204. Hemophilia Medication Customers List Table 205. Research Programs/Design for This Report Table 206. Authors List of This Report Table 207. Secondary Sources Table 208. Primary Sources List of Figures Figure 1. Hemophilia Medication Image Figure 2. Global Hemophilia Medication Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hemophilia Medication Market Size (2021-2032) & (US$ Million) Figure 4. Global Hemophilia Medication Sales (2021-2032) & (K Units) Figure 5. Blood Products Image Figure 6. Global Blood Products Sales YoY Growth (2021-2032) & (K Units) Figure 7. Genetically Engineered Product Image Figure 8. Global Genetically Engineered Product Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Hemophilia Medication Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Hemophilia Medication Market Share by Type 2025 VS 2032 Figure 11. North America Hemophilia Medication Sales Market Share in Volume by Type in 2025 Figure 12. North America Hemophilia Medication Sales Market Share in Value by Type in 2025 Figure 13. Europe Hemophilia Medication Sales Market Share in Volume by Type in 2025 Figure 14. Europe Hemophilia Medication Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Hemophilia Medication Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Hemophilia Medication Sales Market Share in Value by Type in 2025 Figure 17. Latin America Hemophilia Medication Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Hemophilia Medication Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Hemophilia Medication Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Hemophilia Medication Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Hemophilia Medication Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hemophilia A Image Figure 24. Global Hemophilia A Sales YoY Growth (2021-2032) & (K Units) Figure 25. Hemophilia B Image Figure 26. Global Hemophilia B Sales YoY Growth (2021-2032) & (K Units) Figure 27. Global Hemophilia Medication Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Hemophilia Medication Market Share by Application 2025 VS 2032 Figure 29. North America Hemophilia Medication Sales Market Share in Volume by Application in 2025 Figure 30. North America Hemophilia Medication Sales Market Share in Value by Application in 2025 Figure 31. Europe Hemophilia Medication Sales Market Share in Volume by Application in 2025 Figure 32. Europe Hemophilia Medication Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific Hemophilia Medication Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific Hemophilia Medication Sales Market Share in Value by Application in 2025 Figure 35. Latin America Hemophilia Medication Sales Market Share in Volume by Application in 2025 Figure 36. Latin America Hemophilia Medication Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa Hemophilia Medication Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa Hemophilia Medication Sales Market Share in Value by Application in 2025 Figure 39. North America Hemophilia Medication Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 40. North America Hemophilia Medication Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America Hemophilia Medication Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America Hemophilia Medication Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Hemophilia Medication Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. Europe Hemophilia Medication Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Hemophilia Medication Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Hemophilia Medication Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific Hemophilia Medication Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Asia-Pacific Hemophilia Medication Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Hemophilia Medication Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Asia-Pacific Hemophilia Medication Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Hemophilia Medication Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Latin America Hemophilia Medication Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Hemophilia Medication Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Hemophilia Medication Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa Hemophilia Medication Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Middle East and Africa Hemophilia Medication Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Hemophilia Medication Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Middle East and Africa Hemophilia Medication Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Hemophilia Medication Value Chain Figure 60. Key Raw Materials Price Figure 61. Manufacturing Cost Structure Figure 62. Hemophilia Medication Production Mode & Process Figure 63. Direct Comparison with Distribution Share Figure 64. Distributors Profiles Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Blood Products
  • Genetically Engineered Product
Applications
  • Hemophilia A
  • Hemophilia B
Companies covered
  • Bio Products Laboratory (BPL)
  • BioMarin Pharmaceutical
  • CSL Behring
  • Grifols
  • Kedrion Biopharma
  • LFB Group
  • Novo Nordisk
  • Octapharma
  • Takeda Pharmaceutical
  • Bayer
  • Gensciences
  • HuaLan Bio
  • Pfizer
  • Roche
  • Sanofi
  • Shanghai RAAS

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hemophilia Medication Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Hemophilia Medication Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Hemophilia Medication Market by Type
  6. 1.3.1 Blood Products
  7. 1.3.2 Genetically Engineered Product
  8. 1.4 Global Hemophilia Medication Market Size by Type
  9. 1.4.1 Global Hemophilia Medication Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Hemophilia Medication Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Hemophilia Medication Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Hemophilia Medication Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Hemophilia Medication Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Hemophilia Medication Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Hemophilia Medication Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Hemophilia Medication Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Hemophilia Medication Industry Trends
  2. 2.2 Hemophilia Medication Industry Drivers
  3. 2.3 Hemophilia Medication Industry Opportunities and Challenges
  4. 2.4 Hemophilia Medication Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Hemophilia Medication Revenue (2021-2026)
  2. 3.2 Global Top Players by Hemophilia Medication Sales (2021-2026)
  3. 3.3 Global Top Players by Hemophilia Medication Price (2021-2026)
  4. 3.4 Global Hemophilia Medication Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hemophilia Medication Major Company Production Sites & Headquarters
  6. 3.6 Global Hemophilia Medication Company, Product Type & Application
  7. 3.7 Global Hemophilia Medication Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hemophilia Medication Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hemophilia Medication Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hemophilia Medication Tier 1, Tier 2, and Tier 3
4 Hemophilia Medication Regional Status and Outlook
  1. 4.1 Global Hemophilia Medication Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Hemophilia Medication Historic Market Size by Region
  3. 4.2.1 Global Hemophilia Medication Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Hemophilia Medication Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Hemophilia Medication Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Hemophilia Medication Forecasted Market Size by Region
  7. 4.3.1 Global Hemophilia Medication Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Hemophilia Medication Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Hemophilia Medication Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Hemophilia Medication by Application
  1. 5.1 Hemophilia Medication Market by Application
  2. 5.1.1 Hemophilia A
  3. 5.1.2 Hemophilia B
  4. 5.2 Global Hemophilia Medication Market Size by Application
  5. 5.2.1 Global Hemophilia Medication Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Hemophilia Medication Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Hemophilia Medication Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Hemophilia Medication Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Hemophilia Medication Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Hemophilia Medication Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Hemophilia Medication Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Hemophilia Medication Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Bio Products Laboratory (BPL)
  2. 6.1.1 Bio Products Laboratory (BPL) Company Information
  3. 6.1.2 Bio Products Laboratory (BPL) Business Overview
  4. 6.1.3 Bio Products Laboratory (BPL) Hemophilia Medication Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Bio Products Laboratory (BPL) Hemophilia Medication Product Portfolio
  6. 6.1.5 Bio Products Laboratory (BPL) Recent Developments
  7. 6.2 BioMarin Pharmaceutical
  8. 6.2.1 BioMarin Pharmaceutical Company Information
  9. 6.2.2 BioMarin Pharmaceutical Business Overview
  10. 6.2.3 BioMarin Pharmaceutical Hemophilia Medication Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 BioMarin Pharmaceutical Hemophilia Medication Product Portfolio
  12. 6.2.5 BioMarin Pharmaceutical Recent Developments
  13. 6.3 CSL Behring
  14. 6.3.1 CSL Behring Company Information
  15. 6.3.2 CSL Behring Business Overview
  16. 6.3.3 CSL Behring Hemophilia Medication Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 CSL Behring Hemophilia Medication Product Portfolio
  18. 6.3.5 CSL Behring Recent Developments
  19. 6.4 Grifols
  20. 6.4.1 Grifols Company Information
  21. 6.4.2 Grifols Business Overview
  22. 6.4.3 Grifols Hemophilia Medication Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Grifols Hemophilia Medication Product Portfolio
  24. 6.4.5 Grifols Recent Developments
  25. 6.5 Kedrion Biopharma
  26. 6.5.1 Kedrion Biopharma Company Information
  27. 6.5.2 Kedrion Biopharma Business Overview
  28. 6.5.3 Kedrion Biopharma Hemophilia Medication Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Kedrion Biopharma Hemophilia Medication Product Portfolio
  30. 6.5.5 Kedrion Biopharma Recent Developments
  31. 6.6 LFB Group
  32. 6.6.1 LFB Group Company Information
  33. 6.6.2 LFB Group Business Overview
  34. 6.6.3 LFB Group Hemophilia Medication Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 LFB Group Hemophilia Medication Product Portfolio
  36. 6.6.5 LFB Group Recent Developments
  37. 6.7 Novo Nordisk
  38. 6.7.1 Novo Nordisk Company Information
  39. 6.7.2 Novo Nordisk Business Overview
  40. 6.7.3 Novo Nordisk Hemophilia Medication Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Novo Nordisk Hemophilia Medication Product Portfolio
  42. 6.7.5 Novo Nordisk Recent Developments
  43. 6.8 Octapharma
  44. 6.8.1 Octapharma Company Information
  45. 6.8.2 Octapharma Business Overview
  46. 6.8.3 Octapharma Hemophilia Medication Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Octapharma Hemophilia Medication Product Portfolio
  48. 6.8.5 Octapharma Recent Developments
  49. 6.9 Takeda Pharmaceutical
  50. 6.9.1 Takeda Pharmaceutical Company Information
  51. 6.9.2 Takeda Pharmaceutical Business Overview
  52. 6.9.3 Takeda Pharmaceutical Hemophilia Medication Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Takeda Pharmaceutical Hemophilia Medication Product Portfolio
  54. 6.9.5 Takeda Pharmaceutical Recent Developments
  55. 6.10 Bayer
  56. 6.10.1 Bayer Company Information
  57. 6.10.2 Bayer Business Overview
  58. 6.10.3 Bayer Hemophilia Medication Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Bayer Hemophilia Medication Product Portfolio
  60. 6.10.5 Bayer Recent Developments
  61. 6.11 Gensciences
  62. 6.11.1 Gensciences Company Information
  63. 6.11.2 Gensciences Business Overview
  64. 6.11.3 Gensciences Hemophilia Medication Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Gensciences Hemophilia Medication Product Portfolio
  66. 6.11.5 Gensciences Recent Developments
  67. 6.12 HuaLan Bio
  68. 6.12.1 HuaLan Bio Company Information
  69. 6.12.2 HuaLan Bio Business Overview
  70. 6.12.3 HuaLan Bio Hemophilia Medication Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 HuaLan Bio Hemophilia Medication Product Portfolio
  72. 6.12.5 HuaLan Bio Recent Developments
  73. 6.13 Pfizer
  74. 6.13.1 Pfizer Company Information
  75. 6.13.2 Pfizer Business Overview
  76. 6.13.3 Pfizer Hemophilia Medication Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Pfizer Hemophilia Medication Product Portfolio
  78. 6.13.5 Pfizer Recent Developments
  79. 6.14 Roche
  80. 6.14.1 Roche Company Information
  81. 6.14.2 Roche Business Overview
  82. 6.14.3 Roche Hemophilia Medication Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Roche Hemophilia Medication Product Portfolio
  84. 6.14.5 Roche Recent Developments
  85. 6.15 Sanofi
  86. 6.15.1 Sanofi Company Information
  87. 6.15.2 Sanofi Business Overview
  88. 6.15.3 Sanofi Hemophilia Medication Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Sanofi Hemophilia Medication Product Portfolio
  90. 6.15.5 Sanofi Recent Developments
  91. 6.16 Shanghai RAAS
  92. 6.16.1 Shanghai RAAS Company Information
  93. 6.16.2 Shanghai RAAS Business Overview
  94. 6.16.3 Shanghai RAAS Hemophilia Medication Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Shanghai RAAS Hemophilia Medication Product Portfolio
  96. 6.16.5 Shanghai RAAS Recent Developments
7 North America by Country
  1. 7.1 North America Hemophilia Medication Sales by Country
  2. 7.1.1 North America Hemophilia Medication Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Hemophilia Medication Sales by Country (2021-2026)
  4. 7.1.3 North America Hemophilia Medication Sales Forecast by Country (2027-2032)
  5. 7.2 North America Hemophilia Medication Market Size by Country
  6. 7.2.1 North America Hemophilia Medication Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Hemophilia Medication Market Size by Country (2021-2026)
  8. 7.2.3 North America Hemophilia Medication Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Hemophilia Medication Sales by Country
  2. 8.1.1 Europe Hemophilia Medication Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Hemophilia Medication Sales by Country (2021-2026)
  4. 8.1.3 Europe Hemophilia Medication Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Hemophilia Medication Market Size by Country
  6. 8.2.1 Europe Hemophilia Medication Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Hemophilia Medication Market Size by Country (2021-2026)
  8. 8.2.3 Europe Hemophilia Medication Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Hemophilia Medication Sales by Country
  2. 9.1.1 Asia-Pacific Hemophilia Medication Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Hemophilia Medication Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Hemophilia Medication Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Hemophilia Medication Market Size by Country
  6. 9.2.1 Asia-Pacific Hemophilia Medication Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Hemophilia Medication Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Hemophilia Medication Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Hemophilia Medication Sales by Country
  2. 10.1.1 South America Hemophilia Medication Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Hemophilia Medication Sales by Country (2021-2026)
  4. 10.1.3 South America Hemophilia Medication Sales Forecast by Country (2027-2032)
  5. 10.2 South America Hemophilia Medication Market Size by Country
  6. 10.2.1 South America Hemophilia Medication Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Hemophilia Medication Market Size by Country (2021-2026)
  8. 10.2.3 South America Hemophilia Medication Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Hemophilia Medication Sales by Country
  2. 11.1.1 Middle East and Africa Hemophilia Medication Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Hemophilia Medication Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Hemophilia Medication Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Hemophilia Medication Market Size by Country
  6. 11.2.1 Middle East and Africa Hemophilia Medication Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Hemophilia Medication Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Hemophilia Medication Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Hemophilia Medication Value Chain Analysis
  2. 12.1.1 Hemophilia Medication Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Hemophilia Medication Production Mode & Process
  7. 12.2 Hemophilia Medication Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Hemophilia Medication Distributors
  10. 12.2.3 Hemophilia Medication Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst